Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Holtzman

Showing results (11-20 of 602) with videos related to

Pageof 61
Sort By:
Journal of Molecular Neuroscience : MN|June 8, 2004
In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathologyDavid M Holtzman
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 14, 2019
Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factorsChanung Wang, David M Holtzman
JAMA Neurology|October 7, 2014
Human neurons derived from induced pluripotent stem cells as a new platform for preclinical drug screening and developmentFan Liao, David M Holtzman
Journal of Neurological Disorders|October 14, 2014
The Ultrastructural Identity of Alzheimer's Pathology: Lessons from Animal ModelsKrikor Dikranian, David M Holtzman
Cold Spring Harbor Perspectives in Medicine|January 8, 2017
Antibody Therapeutics Targeting Aβ and TauGilbert Gallardo, David M Holtzman
The Journal of Experimental Medicine|May 7, 2014
B-RAF unlocks axon regenerationValeria Cavalli, David M Holtzman
Nature Medicine|July 2, 2025
Rethinking TREM2 as a target for Alzheimer's disease after the INVOKE-2 trial failureMarco Colonna, David M Holtzman
Science (New York, N.Y.)|November 13, 2010
Medicine. Prion-like behavior of amyloid-betaJungsu Kim, David M Holtzman
Immunity|November 9, 2022
Emerging roles of innate and adaptive immunity in Alzheimer's diseaseXiaoying Chen, David M Holtzman
Neuron|March 4, 2021
Targeting pre-synaptic tau accumulation: a new strategy to counteract tau-mediated synaptic loss and memory deficitsMaud Gratuze, David M Holtzman
Pageof 61

Showing results (11-20 of 602) with videos related to

Sort By:
Pageof 61
Journal of Molecular Neuroscience : MN|June 8, 2004
In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathologyDavid M Holtzman
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 14, 2019
Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factorsChanung Wang, David M Holtzman
JAMA Neurology|October 7, 2014
Human neurons derived from induced pluripotent stem cells as a new platform for preclinical drug screening and developmentFan Liao, David M Holtzman
Journal of Neurological Disorders|October 14, 2014
The Ultrastructural Identity of Alzheimer's Pathology: Lessons from Animal ModelsKrikor Dikranian, David M Holtzman
Cold Spring Harbor Perspectives in Medicine|January 8, 2017
Antibody Therapeutics Targeting Aβ and TauGilbert Gallardo, David M Holtzman
The Journal of Experimental Medicine|May 7, 2014
B-RAF unlocks axon regenerationValeria Cavalli, David M Holtzman
Nature Medicine|July 2, 2025
Rethinking TREM2 as a target for Alzheimer's disease after the INVOKE-2 trial failureMarco Colonna, David M Holtzman
Science (New York, N.Y.)|November 13, 2010
Medicine. Prion-like behavior of amyloid-betaJungsu Kim, David M Holtzman
Immunity|November 9, 2022
Emerging roles of innate and adaptive immunity in Alzheimer's diseaseXiaoying Chen, David M Holtzman
Neuron|March 4, 2021
Targeting pre-synaptic tau accumulation: a new strategy to counteract tau-mediated synaptic loss and memory deficitsMaud Gratuze, David M Holtzman
Pageof 61